



11th CONFERENCE OF THE EUROPEAN HIDRADENITIS SUPPURATIVA FOUNDATION

Innovating the HS future.

February 9–11, 2022 | Virtual



FINAL PROGRAM

www.ehsf2022.com

TABLE OF CONTENTS

01	WELCOME MESSAGE	05
02	ABOUT EHSF	
	Our history	05
	1 st International Hidradenitis Suppurativa Research Symposium	05
	Last Hsf, Inc. Board with European Participation	05
	Inauguration of EHSF e.V.	06
	Founding Members	06
	Congresses	06
	Our Goals	07
03	COMMITTEES	
	Organizing Committee	9
	Scientific Committee	10
04	FEBRUARY 10, 2021	
	Overview	11
	Program	12
05	FEBRUARY 11, 2021 PROGRAM THU	
	Overview Program	13
	Program	14
06	FEBRUARY 12, 2021 PROGRAM FRI	
	Overview Program	19
	Program	20
07	POSTERS	27
07	GENERAL INFORMATION	34

Stand: 9 February, 2021

WELCOME MESSAGE

Dear colleagues,

the EHSF e.V. celebrates 15 years of fascinating work mirrored in a current publication of 43 coauthors (Exp Dermatol 2020;29:1154–70), which summarized ongoing hidradenitis suppurativa (HS) research and clinical activities around the globe.

After the international thematic conferences in Dessau (2006), San Francisco (2009), Brussels (2014 and 2015), Berlin (2016), Copenhagen (2017), Rotterdam (2018), Wroclaw (2019) and Athens (2020) we had planed to organize the 10th International EHSF Conference as a worldwide face-to-face event. The pandemic has obliged us, however, to offer a virtual event, which is a new experience for us and, despite of that, is going to fulfill our target to provide a high level scientific event on the ongoing and future research development and innovations on HS. Moreover, we want to achieve our initial purpose to encourage international cooperation in the field.

Since the legentary, pioneer days many things have changed to the better. The interest to the disease and the scientific work performed by increasing numbers of clinician and scientists have grown exponentially. HS has found its home in dermatology. Patients have been organized in several national self-aid groups. A first compound for medical treatment has been registered with many more currently being into clinical studies. At last, the EHSF e.V. has grown up, providing significant contributions in the field through valuable cooperative works of its members in discovering the molecular etiology, comorbid factors and biomarkers, and establishing diagnostic and classification criteria, outcome measure instruments and guidelines for the treatment of the disease.

These huge developments, which supported a better understanding of HS and the needs of medical and psychological care of HS patients but also the targets for the years to come will be the central subjects of this scientific event. Parallely, EHSF e.V. opens its doors to invite all caring physicians and scientists, independently of their specialization, to participate, since the emerging comorbidity of HS requires an interdisciplinary approach. Our purpose is to construct a scientific programme of high impact providing current information on research and clinical relevance on HS. The invited speakers and those chosen among you, who will submit abstracts, include both experts in the field, who are motivators for young upcoming specialists, but also young scientists and students working or wishing to work in this fascinating field in the future as well as the partners of the pharmaceutical industry, who are active in the field.

Participants will have the opportunity to share their knowledge and perspectives and to gain a better insight in HS. We have no doubt that your virtual journey to Europe will be an interesting experience and we will make our best efforts that your scientific expectations and networking wishes will be fulfilled.

On behalf of the EHSF e.V.

Prof. Dr. med. Prof. honoraire Dr. h.c. Christos C. Zouboulis, Dessau



ABOUT EHSF

OUR HISTORY

Founding of HSF, Inc.

In 2005, Mrs. Michele Barlow, a patient from San Diego, CA, USA, organized first funding to initiate the Hidradenitis Suppurativa Foundation, Inc. (HSF, Inc.), a tax-deducted organization according to the US law. In addition to Mrs. Barlow as president and co-founder, the first board of HSF Inc. included Mr. Robert Howes, San Diego, CA, USA, vice president and co-founder, Prof. Dr. Ralf Paus, Luebeck, Germany, director of basic research and co-founder, Prof. Dr. Christos C. Zouboulis, Dessau, Germany, director of clinical research and co-founder, Mrs. Christine E. Pasela, San Diego, CA, USA, Mrs. Sylvia Shawcross, Chelsea, Quebec, Canada, Mrs. Mary Veta, San Diego, CA, USA, and Mrs. Lynn Edward Wedell, San Diego, CA, USA. Experimental Dermatology became the official scientific journal of the HSF, Inc.

1st INTERNATIONAL HIDRADENITIS SUPPURATIVA RESEARCH SYMPOSIUM

The 1st International Hidradenitis Suppurativa Research Symposium took place on 30.03 – 02.04.2006 in Dessau, Germany. The milestones of the Symposium were the so-called Dessauer definition of the disease and the HSF 2006 Outstanding Investigator Award presented to Prof. Gregor B. E. Jemec. The attendees of this legendary meeting were Dr. David R. Adams, USA; Dr. Andreas Altenburg, Germany; Mrs. Michelle Barlow,

USA; Dr. Martina Brunner, Germany; Dr. George Cotsarelis, USA; Dr. William Danby, USA; Dr. Alain Dupuy, France; Dr. Sabine Fimmel, Germany; Dr. Wolfgang Hartschuh, Germany; Dr. Dolores Herreros, Spain; Dr. Dorothee Hochheim, Germany; Mr. Robert Howes, USA; Dr. Peter Hull, Canada; Dr. Gregor Jemec, Denmark; Dr. Yvonne Kroening, Germany; Dr. Ichiro Kurokawa, Japan; Dr. Hjalmar Kurzen, Germany; Dr. Evgenia Makrantonaki, Germany; Dr. Anirban Mandal, UK; Dr. Lynette Margesson, USA; Dr. Wolfgang C. Marsch, Germany; Dr. W.H. Irwin McLean, Scotland; Dr. Samuel L. Moschella, USA; Dr. Ralf Paus, Germany; Dr. Uppala Radhakrishna, USA; Dr. Jean Revuz, France; Dr. Jihai Shi, Germany; Dr. Rodney Sinclair, Australia; Dr. John Sundberg, USA; Dr. Gilles Tachon, France; Dr. Antje Thielitz, Germany; Dr. Athanasios Theodoridis, Germany; Dr. Frangiski Tsatsou, Germany; Dr. Jan von der Werth, UK; and Dr. Christos C. Zouboulis, Germany.

LAST HSF, INC. BOARD WITH EUROPEAN PARTICIPATION

On 15.02.2012 a new HSF, Inc. board was elected (and re-elected on 11.02.2018) with Prof. Dr. Christos C. Zouboulis, Dessau, Germany, President and responsible for hidradenitis suppurativa/acne inversa guidelines, Prof. Gregor B.E. Jemec, Copenhagen, Denmark, vice president and responsible for clinical research, Prof. Dr. Ralf Paus, Luebeck, Germany/Manchester, UK, vice president and responsible for experimental research, Mrs. Michelle Barlow, San Diego, CA, USA (former president,

ex officio), treasurer and responsible for the Foundation, Prof. Richard Gallo, San Diego, CA, USA, Dr. Ichiro Kurokawa, Nishinomiya, Japan, Dr. George Varigos, Melbourne, Australia, Dr. Jan Lapins, Stockholm, Sweden, Dr. Paul Hazen, Westlake, OH, USA, responsible for patients' communication and for the HSF Inc. website, Thomas Winkler, Germany, patients' representative, president Deutsche Interessengemeinschaft Akne inversa e.V., and Dr. Hessel H. van der See, Rotterdam, The Netherlands.

Despite the excellent and close cooperation among the involved scientists, the European Board members have recognized that bureaucratic issues in the USA made it more and more difficult for non-US citizens to run efficiently a US association. Therefore, Prof. Zouboulis resigned as HSF, Inc. president and member of the board on 27.02.2013 followed by Prof. Paus, leaving the leadership of the HSF, Inc. to US colleagues with Dr. Paul Hazen as new HSF, Inc. president from 02.03.2013. During its first meeting on 24.03.2014 the new HSF, Inc. board has granted Mrs. Michelle Barlow, Prof. Christos C. Zouboulis and Prof. Ralf Paus the honorary Founders HSF, Inc. Membership.

INAUGURATION OF EHSF E.V.

The European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) has been inaugurated on 29.09.2012 in Prague, Czech Republic as independent, sister society of HSF, Inc. The EHSF e.V. has been registered and recognized as a non-profit, public benefit organization (gemeinnuetziger e.V.) according to the German law. General assemblies, take place annually during the annual International

Conference of the Society.

FOUNDING MEMBERS

- Dr. Jurr Boer, Deventer/The Netherlands
- Prof. Dr. Veronique del Marmol, Brussels/Belgium
- Dr. Nemesha Desai, London/United Kingdom
- Dr. Deirdre Nathalie Dufour, Kalundborg/Denmark
- Dr. Lennart Emtestam, Stockholm/Sweden
- Prof. Dr. Gregor B.E. Jemec, Roskilde/Denmark
- Dr. Łukasz Matusiak, Wroclaw/Poland
- Prof. Dr. Thrasivoulos Tzellos, Harstad, Troms/Norway
- Thomas Winkler, Lüdinghausen/Germany
- Dr. Hessel H. van der Zee, Rotterdam/The Netherlands
- Prof. Dr. Christos C. Zouboulis, Dessau-Rosslau/Germany

CONGRESSES

The 2nd International Hidradenitis Suppurativa Research Symposium took place on 05.03.2009 in San Francisco, IL, USA.

The 3rd International Hidradenitis Suppurativa Research Symposium (first of the EHSF e.V.) took place on 27.-28.02.2014 in Brussels, Belgium.

The 4th International Hidradenitis Suppurativa Research Symposium took place on 19.-20.02.2015 in Brussels, Belgium.

The 5th International Hidradenitis Suppurativa Conference, which was for the first time also open for non-members of the Society, took place on 10.-12.02.2016 in Berlin, Germany with 192 participants and 76 scientific contributions.

The 6th International Hidradenitis Suppurativa Conference took place on 8.-10.02.2017 in Copenhagen, Denmark with 202 participants and 77 scientific contributions.

The 7th International Hidradenitis Suppurativa Conference took place on 10.-12.02.2018 in Rotterdam, The Netherlands with more than 250 participants and 82 scientific contributions.

The 8th International Hidradenitis Suppurativa Conference took place on 10.-12.02.2019 in Wroclaw, Poland with 406 participants and 119 scientific contributions.

The 9th International Hidradenitis Suppurativa Conference took place on 5.-7.02.2020 in Athens, Greece. 422 participants from 48 countries with 137 scientific contributions participated at the conference.

The 10th International Hidradenitis Suppurativa Conference takes place – due to the COVID-19 pandemic – at a digital mode – 10.-12.02.2021. 141 scientific contributions will be presented and over 638 participants have been registered so far.

The 10th virtual conference of the EHSF was certified by the Medical Association of Saxony-Anhalt with 16 CME.

OUR GOALS

- The European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) pursues

exclusively and directly charitable purposes within the meaning of the “tax-privileged purposes” of the tax code. Goal of the association is the promotion of science and research in field of the disease hidradenitis suppurativa/acne inversa.

- The goal of the association is raising funds for the promotion of research projects in the field of the disease hidradenitis suppurativa/acne inversa also to be achieved by support from other tax-exempt entities, public corporations or foreign entities whose activity is in line with the German Charity Law.
- Goal of the association is also the training of physicians, patients and laypersons.
- These goals are to be achieved
 - through raising funds for the support of scientific meetings for education of physicians, patients and laypersons also from other tax-exempt bodies, public corporations or foreign corporations whose business is through raising funds for the support of scientific meetings for continuing education of physicians, patients and laypersons in accordance with the German Charity Law,
 - through lectures of educational character and
 - through public relations. Goal of the association is also raising funds for the promotion of public health care in the field of the disease hidradenitis suppurativa/acne inversa also from other tax-exempt entities, public corporations or foreign corporations whose activities are in line with the German non-profit law.

WEBINAR SERIES

abbvie

360° Perspectives on Challenging HS Cases: What happened next?

Wednesday, 10 February 2021

Join us for our webinar series and find out from a panel of 14 international expert dermatologists specializing in hidradenitis suppurativa (HS) what happened after these patients started treatment.



Sofia

Highly inflammatory
10:00 CET

Dr. Ruaa Al Harithy
(Saudi Arabia)

Dr. Pierre-André Becherel
(France)

Dr. Nobukazu Hayashi (Japan)

Dr. Maria Cecilia Rivitti
Machado (Brazil)

Dr. Laura Savage (UK)

Dr. Thrasyvoulos Tzellos
(Norway)

Dr. Hessel van der Zee
(Netherlands)



Adam

Combination therapy
14:00 CET

Dr. Monika Arenbergerova
(Czechia)

Dr. Falk Bechara (Germany)

Dr. Vincenzo Bettoli (Italy)

Dr. Antonio Martorell (Spain)

Dr. Lukasz Matusiak
(Poland)

Dr. Saxon Smith (Australia)

Dr. Mariano Suppa
(Belgium)

WATCH WEBINAR

ALL-HUMD-210016

EHSF ORGANIZING COMMITTEE



GREGOR B.E. JEMEC

(Roskilde, Denmark)



VERONIQUE DEL MARMOL

(Brussels, Belgium)



ERROL P. PRENS

(Rotterdam, The Netherlands)



THRASYVOULOS TZELLOS

(Bodø, Norway)



CHRISTOS C. ZOUBOULIS

(Dessau, Germany)



European
Reference
Networks



The Department of Dermatology, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium; the Department of Dermatology, Zealand University Hospital, University of Copenhagen, Roskilde, Denmark; the Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany; and the Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands are health care providers of the European Reference Network of Rare and Complex Skin Diseases (ERN Skin)

SCIENTIFIC COMMITTEE

Farida Benhadou (Brussels)

Vincenzo Bettoli (Ferrara)

Angel S. Byrd (Washington DC)

Nisha S. Chandran (Singapore)

Veronique del Marmol (Brussels)

John W. Frew (Sydney)

Evangelos J. Giamarellos-Bourboulis (Athens)

Katalin Glasenhardt (Szeged)

Philippe Guillem (Écully)

Wayne Gulliver (St. John's)

Barbara Hörvath (Groningen)

Sophie Hue (Créteil)

John R. Ingram (Cardiff)

Gregor B.E. Jemec (Roskilde)

Olivier Join-Lambert (Caen)

Joslyn S. Kirby (Hershey)

Mark G. Kirchhof (Ottawa)

Antonio Martorell (Manises)

Angelo V. Marzano (Milan)

Łukasz Matusiak (Wrocław)

Luigi, Naldi (Bergamo)

Georgios Nikolakis (Dessau)

Elizabeth O'Brien (Montreal)

Maurizio Podda (Darmstadt)

Errol P. Prens (Rotterdam)

Ditte M. Saunte (Roskilde)

Andrea Szegedi (Debrecen)

Thrasylvoulos Tzellos (Bodø)

Kelsey R. Van Straalen (Rotterdam)

Baoxi Wang (Peking)

Thomas Wild (Dessau)

Hessel H. van der Zee (Rotterdam)

Christos C. Zouboulis (Dessau)

WEDNESDAY PROGRAM OVERVIEW



Wednesday, February 10, 2021

08.00–18.00 (CET)

Sponsor Exhibition (digital booths) – Meetings with Sponsor Representatives



10.00–11.30 (CET)

AbbVie Satellite Symposium

360o perspectives on challenging HS cases: Sophia, High Inflammatory. What happened next?



14.00–15.30 (CET)

AbbVie Satellite Symposium

360o perspectives on challenging HS cases: Adam, Combination Therapy. What happened next?



15.30–18.00 (CET)

Patient Association Representatives Chat Room

**10th EHSF Conference Abstract Book
Poster Viewing**

	TITLE	
08.00-18.00	Sponsor Exhibition (digital booths) – Meetings with Sponsor Representatives	 All day 10th EHSF Conference Abstract Book
10.00-11.30	AbbVie Satellite Symposium 360o perspectives on challenging HS cases: Sophia, High Inflammatory. What happened next? <i>Christopher Savage (Altamonte Springs),</i> <i>Thrasylvoulos Tzellos (Bodø),</i> <i>Maria Rivitti Machado (Sao Paolo),</i> <i>Pierre-Andre Becherel (Antony),</i> <i>Hessel H. van der Zee (Rotterdam),</i> <i>Nobukazu Hayashi (Tokyo),</i> <i>Ru'aa Alharithy (Riyadh)</i>	 All day Poster Viewing
14.00-15.30	AbbVie Satellite Symposium 360o perspectives on challenging HS cases: Adam, Combination Therapy. What happened next? <i>Antonio Martorell (Manises)</i> <i>Mariano Suppa (Brussels),</i> <i>Falk G. Bechara (Bochum),</i> <i>Monika Arenbergerova (Prague), Saxon D. Smith (Gosford),</i> <i>Łukasz Matusiak (Wrocław),</i> <i>Vincenzo Bettoli (Ferrara)</i>	
15.30-18.00	Patient Association Representatives Chat Room Coordination: <i>Farida Benhadou (Brussels), Philippe Guillem (Écully)</i> Participants (until 31.01.2021): <i>Belgian HS Patients Association, Deutsche Akne Inversa Patientenvereinigung, Dutch HS Patient Organisation, HS Connect USA, HS International Sweden, Irish HS Patients Organization, mullewupp Akne inversa Selbsthilfe e.V., Norwegian HS Patients Organization, Patientforeningen HS Danmark</i>	

THURSDAY PROGRAM OVERVIEW

 **Thursday, February 11, 2021**
08.00–19.15 (CET)

 08.00–09.00 (CET)

EHSF e.V. General Assembly
(only Members)

 09.00–10.00 (CET)

HS Nursing School

 10.00–10.10 (CET)

Welcome Address

 10.10–10.30 (CET)

**Opening lecture: 15 years hidradenitis
suppurativa: Then and today**

 10.30–13.45 (CET)

**Scientific Session 1 – Epidemiology and
Diagnostic Tools (Clinical Phenotypes,
Outcome Measures)**

 13.45–15.15 (CET)

Poster Session

 15.15–17.15 (CET)

**Scientific Session 2a – Basic and
Translational Experimental Research**
(Genetics, Immunology, Biomarkers
Comorbidities, Registries)

 17.15–17.30 (CET)

Intermission

 17.30–19.15 (CET)

**Scientific Session 2b – Basic and
Translational Experimental Research**
(Genetics, Immunology, Biomarkers
Comorbidities, Registries)

Sponsor Exhibition (digital booths) – Meetings with Sponsor Representatives
Poster Viewing

	TITLE	
08.00–9.00	EHSF e.V. General Assembly <i>(only Members)</i>	 All day 10th EHSF Conference Abstract Book
09.00–10.00	HS Nursing School Coordination: <i>Shani Fisher (Tel Aviv), Veronique del Marmol (Brussels)</i>	 All day Poster Viewing
10.00–10.10	Welcome Address <i>Christos C. Zouboulis (Dessau)</i>	
10.00–10.30	Opening lecture: 15 years hidradenitis suppurativa: Then and today <i>Errol P. Prens (Rotterdam)</i>	
10.30–13.45	Scientific Session 1 – Epidemiology and Diagnostic Tools (Clinical Phenotypes, Outcome Measures) Main learning objectives of this session are ■ to communicate new data on HS epidemiology, clinical phenotypes and comorbidities ■ to present the development on more robust outcome measures ■ to present new physician- and patient-supporting assessment technologies Chairs: <i>Afsaneh Alavi (Rochester), Jacek C. Szepietowski (Wroclaw)</i> Epidemiology of hidradenitis suppurativa <i>John R. Ingram (Cardiff)</i> Hidradenitis suppurativa phenotypes <i>Hessel van der Zee (Rotterdam)</i> Phenotypes of hidrosadenitis suppurativa <i>Luigi Naldi (Bergamo)</i> Comorbidities of hidradenitis suppurativa: epidemiological associations <i>Katalin Glasenhardt (Szeged)</i>	

10.30-13.45**Comorbidities of hidradenitis suppurativa: Interpretation and clinical implications***John W. Frew (Sydney)***Structured patient-reported quantifiable records as outcome measures***Gregor B.E. Jemec (Roskilde)***Development and validation of a IHS4 dichotomous outcome to assess treatment effect***Thrasyvoulos Tzello, A. Kyrgidis, A. Alavi, W. Gulliver, G. Jemec, M. Lowes, A. Marzano, E.P. Prens, C.J. Sayed, K.R. van Straalen, H.H. van der Zee, C.C. Zouboulis (Bodø/Tromsø/Thessaloniki/Rochester/St. John's/Roskilde/New York/Milan/Rotterdam/Chapel Hill/Dessau)***Hidradenitis suppurativa phenotypes, classification, refined Hurley***Barbara Hörvath (Groningen)***DLQI scores in hidradenitis suppurativa patients***P.K. Krajewski, Ł. Matusiak, E. von Stebut, M. Schultheis, U. Kirschner, G. Nikolakis, Jacek C. Szepietowski (Wrocław/Cologne/Mainz/Dessau)***Pain in hidradenitis suppurativa***Elisabeth O'Brien (Montreal)***Pain Index: A new prospective hidradenitis suppurativa patient-reported outcome measure instrument***Christos C. Zouboulis (Dessau)***Impact of individual lesions of hidradenitis suppurativa in the quality of life***Maria Mouktaroudi, V. Tzanetakou, S. Micha, A. Bolanou, T. Kanni, S. Rellou, E.J. Giannarellos-Bourboulis (Athens)***Convergent validity of suffering and quality of life as measured by the Hidradenitis Suppurativa Quality of Life***Christoffer Kursawe Larsen, R. Kjærsgaard Andersen, J. Kirby, J. Tan, D.M.L. Saunte, G.B.E. Jemec (Roskilde/Hershey/London(ON))*

13.45-15.15

Poster Session

15.15-17.15

Scientific Session 2a – Basic and Translational Experimental Research (Genetics, Immunology, Biomarkers Comorbidities, Registries)

Main learning objectives of this session are

- to learn what is new on HS genetics and biomarker research
- to evaluate specific fields of HS, such as syndromic and pediatric varieties
- to communicate the current status and procedures in the development of HS registries and how they can support HS research

Chairs:

*Gregor B.E. Jemec (Roskilde),
Veronique del Marmol (Brussels)*

Biomarkers in hidradenitis suppurativa

Andrea Szegedi (Debrecen)

Involvement of the innate immune system in the hidradenitis suppurativa pathogenesis

Sophie Hue (Créteil)

Stage-dependent autoantibodies and promotion of proinflammatory cytokines in hidradenitis suppurativa

C. Carmona-Rivera, L.J. O'Neil, E. Patino, W.D. Shipman, C. Zhu, Q.-Z. Li, M.L. Kerns, L.A. Barnes, M.J. Kaplan, G.A. Okoye, Angel S. Byrd (Bethesda/Winnipeg/New York/Dallas/Baltimore/Stanford/Washington DC)

No evident systemic terminal complement pathway activation in hidradenitis suppurativa

L.M. Prens, C.B. Ardon, 3, Kelsey R. van Straalen, H.H. van der Zee, M. A. J. Seelen, J. D. Laman, E. P. Prens, B. Horváth, J. Damman (Groningen/Rotterdam)

The dose-response relationship between tobacco smoking and hidradenitis suppurativa

Axel P. Villani, L. Donzier, F. Benhadou, P. Guillem (Lyon/Paris/Brussels)

15.15–19.15

Comparison of insulin resistance between hidradenitis suppurativa and psoriasis patients on anti-TNF- α therapy omitting confounding factors

Elia Rosi, M.T. Fastame, A. Di Cesare, F. Ricceri, F. Prignano (Florence)

Syndromic hidradenitis suppurativa – part 1

Angelo M. Marzano (Milan)

Syndromic hidradenitis suppurativa – part 2

Georgios Nikolakis, K. Kaleta, C.C. Zouboulis (Dessau/Krakow)

17.15–17.30

Intermission

17.30–19.15

Scientific Session 2b – Basic and Translational Experimental Research (Genetics, Immunology, Biomarkers Comorbidities, Registries)

Chairs:

Ditte M.L. Saunte (Roskilde),

Thrasyvoulos Tzello (Bodø)

Main learning objectives of this session are

- to learn what is new on HS genetics and biomarker research
- to evaluate specific fields of HS, such as syndromic and pediatric varieties
- to communicate the current status and procedures in the development of HS registries and how they can support HS research

Improvement of cytokine production capacity from mononuclear cells of patients with hidradenitis suppurativa with the addition of secukinumab

Styliani Micha, D. Stergianou, V. Tzanetakou, T. Kanni, T. Gkavogianni, E.J. Giamarellos-Bourboulis (Athens)

Complement split product C5a is elevated in moderate and severe hidradenitis suppurativa: clinical improvement by targeted therapy coming from the SHINE Study

Evangelos J. Giamarellos-Bourboulis, G.B.E. Jeremec, E.P. Prens, M. Habel, J.C. Szepletowski, H.H. van der Zee, C.C. Zouboulis, C. Sayed (Athens/Roskilde/Rotterdam/Jena/Wroclaw/Dessau/Chapel Hill)

Pediatric hidradenitis suppurativa: epidemiology and comorbidities

Ditte M.L. Saunte (Roskilde)

Pediatric hidradenitis suppurativa - therapeutic management

Farida Benhadou (Brussels)

Whole exome sequencing of 12 unrelated PASH patients suggests the classification of syndromic hidradenitis suppurativa as an autoinflammatory keratinization disease

Lucas Brandão, R. Moura, M. Boniotto, P.M. Tricarico, R. Gratton, C. Moltrasio, G. Genovese, C. Nait-Meddour, A.V. Marzano, S. Crovella (Trieste/Créteil/Milan/Doha)

CRISPR-Cas9 correction of a NCSTN mutation associated with Hidradenitis Suppurativa and Dowling-Degos Disease (DDD) in an induced pluripotent stem cell line (IMRB_06-06) supports NCSTN as novel gene for DDD

Cécile Nait-Meddour, S. Garcovich, O. Feraud, P.M. Tricarico, S. Crovella, K. Perris, M. Boniotto (Créteil/Rome/Trieste/Doha)

Registries - a review

Veronique del Marmol (Brussels)

FRIDAY PROGRAM OVERVIEW

 **Friday, February 12, 2021**
08.00–19.15 (CET)

 08.00–09.30 (CET)

Poster Session

 09.30–11.00 (CET)

Scientific Session 3 – HS around the World (Selected International Contributions)

 11.00–13.00 (CET)

Scientific Session 4a – Treatment Innovations (Clinical Trials, Local Treatment, Systemic Treatment, Surgical Treatment, Imaging)

 13.00–15.00 (CET)

Scientific Symposium on Hidradenitis Suppurativa Treatment Target Molecules and Anti-COVID-19 Measurements (supported by AbbVie)

 15.00–18.00 (CET)

Scientific Session 4b – Treatment Innovations (Clinical Trials, Local Treatment, Systemic Treatment, Surgical Treatment, Imaging)

 18.00–19.00 (CET)

Selected Poster Session – Poster Prizes

 19.00–19.15 (CET)

Conference Closing/Announcements

**Sponsor Exhibition (digital booths) – Meetings with Sponsor Representatives
Poster Viewing**

	TITLE	
08.00–9.30	Poster Session	 All day 10th EHSF Conference Abstract Book
09.30–11.00	Scientific Session 3 – HS around the World (Selected International Contributions) Main learning objectives of this session are ■ to communicate specific issues on HS epidemiology, clinical picture and treatment in different populations and geographic areas of the world ■ to exchange the knowledge development and built up and corroborate international cooperations Chairs: <i>Joslyn Sciacca Kirby (Hershey), Francesca Prignano (Florence)</i> South Asian perspective <i>Nisha Suyien Chandran (Singapore)</i> A nation-wide clinic-based cross-sectional epidemiological study of hidradenitis suppurativa in China <i>Baoxi Wang (Peking)</i> The prevalence of hidradenitis suppurativa in an obese Australian population <i>Kirsty J.L. Wark, A. Tatian, J. Woods, J. Franklin, S. Hocking, T. Markovic, E. Manson, I. Caterson, G. Cains (Liverpool(A)/Camperdown)</i> Hidradenitis suppurativa in Saudi Arabia, quality of life measures <i>Yousef Binamer, Riyadh</i> USA perspective <i>Joslyn Sciacca Kirby (Hershey)</i> Canadian perspective <i>Mark G. Kirchhof (Ottawa)</i>	 All day Poster Viewing

11.00–13.00

Scientific Session 4a – Treatment Innovations (Clinical Trials, Local Treatment, Systemic Treatment, Surgical Treatment, Imaging)

Main learning objectives of this session are

- to summarize the new evidence on biologic, systemic and surgical treatments, their implications in daily clinical practice and how they can shape current treatment strategies and promote better combination of medical and surgical approaches.
- to provide an overview of the current pipeline (phase 2 and 3 studies)
- to discuss how imaging could facilitate rational treatment decision making

Chairs:

*Brian Kirby (Dublin),**Aude Nassif (Paris)*

Effect of antibiotics in hidradenitis suppurativa: addressing the age-old dogmas of antibiotic use in skin inflammatory diseases - Part I

Kelsey R. van Straalen (Rotterdam)

Effect of antibiotics in hidradenitis suppurativa: addressing the age-old dogmas of antibiotic use in skin inflammatory diseases: part 2

Join-Lambert (Caen)

The bacterial microbiome of early inflammatory nodules in hidradenitis suppurativa: an exploratory cross-sectional study

Simone Garcovich, F. De Maio, C. De Simone, B. Posteraro, K. Peris, M. Sanguinetti (Rome)

Response to targeted antibiotherapy in 43 hidradenitis suppurativa patients after failure of a biotherapy

M. Delage, C. Pierre-Audigier, K. Jidar, P. - H. Consigny, O. Join-Lambert, Aude Nassif (Paris/Caen)

Intravenous antibiotics as adjunctive treatment in severe hidradenitis suppurativa: quick to respond, quick to relapse

Anna Dubois, S. Ball, S. Meggitt, P. Hampton (Newcastle upon Tyne)

11.00-13.00

Short courses of ertapenem as a part of conservative treatment strategy in severe hidradenitis suppurativa

E.H. Hristakieva, T.T. Gancheva, K.L. Manuelyan, R.V. Lavcheva, Radostina S. Deliyka (Stara Zagora)

LAight® therapy improves hidradenitis suppurativa
Łukasz Matusiak (Wrocław)

Evaluation of barriers to therapeutic drug monitoring in the management of hidradenitis suppurativa

Yuval Hilerowicz, N. Levin, J. Palmar, A. Halavi, H. Lev-Tov (Tel Aviv/Miami/Minnesota/Toronto/Boca Raton)

13.00-15.00

Scientific Symposium on Hidradenitis Suppurativa Treatment Target Molecules and Anti-COVID-19 Measurements (supported by AbbVie)

Chairs:

Errol P. Prens (Rotterdam),

Christos C. Zouboulis (Dessau)

Part I. HS Treatment Target Molecules

Introduction

Errol P. Prens (Rotterdam)

IL-1α/IL-1αR

Evangelos J. Giamarellos-Bourboulis (Athens)

IL-17A/IL-17A,F/IL-17R

Errol P. Prens (Rotterdam)

IL-23/IL-36

Gregor B.E. Jemec (Roskilde)

JAK

John W. Frew (Sydney)

S100A/IRAK/CXCR

Angelo V. Marzano (Milan)

C5a/C5aR

Christopher J. Sayed (Chapel Hill)

Hormones/Metformin

Georgios Nikolakis (Dessau)

13.00–15.00**PDE4/G-CSF-R***Kerstin Wolk (Berlin)***Discussion***Coordination: Veronique del Marmol (Brussels),
Thrasyvoulos Tzello (Bodø)***Summary***Christos C. Zouboulis (Dessau)***Part II. Anti-COVID-19 Measurements****Introduction***Christos C. Zouboulis (Dessau)*

1. Are HS patients more or less COVID-19 susceptible?
2. Are HS patients under biologics treatment more or less COVID-19 susceptible?
3. Should HS patients be Anti-SARS-Co2-vaccinated?
4. Should biologics treatment interrupted for Anti-SARS-Co2-vaccination?

*Vincenzo Bettoli (Ferrara),**Evangelos J. Giamarellos-Bourboulis (Athens)***Discussion***Coordination: Gregor B.E. Jemec (Roskilde),
Angelo V. Marzano (Milan)***15.00–18.00****Scientific Session 4b – Treatment Innovations (Clinical Trials, Local Treatment, Systemic Treatment, Surgical Treatment, Imaging)**

Main learning objectives of this session are

- to summarize the new evidence on biologic, systemic and surgical treatments, their implications in daily clinical practice and how they can shape current treatment strategies and promote better combination of medical and surgical approaches.
- to provide an overview of the current pipeline (phase 2 and 3 studies)
- to discuss how imaging could facilitate rational treatment decision making

Chairs:

*Evangelos J. Giamarellos-Bourboulis (Athens),
Alejandro Molina Leyva (Granada)*

15.00-18.00

Update on clinical trials in hidradenitis suppurativa

Wayne P. Gulliver (St. John's)

Clinical trials: on-going options for medical treatment

Evangelos J. Giamarellos-Bourboulis (Athens)

Seven years-experience of adalimumab therapy for hidradenitis suppurativa in a real-life dermatologic setting

V. Bettoli, Giulia Odorici, L. Pacetti, R. Forconi, N.

Schettini, P. Zedde, M. Corazza (Ferrara)

Interest of an infliximab boost before adalimumab treatment in severe inflammatory hidradenitis suppurativa

Pierre-Andre Becherel, M. Thomas, M. Dehais, S. Raccah,

J.-C. Moreno (Anthony)

Drug survival of adalimumab and infliximab in hidradenitis suppurativa patients: a daily practice cohort study

L.M. Prens, Silke Klasiena Bouwman, P. Aarts, S. Arends,

K.R. van Straalen, K. Dudink, H.H. van der Zee, E.P. Prens,

B. Horváth (Groningen/Rotterdam)

A randomized, placebo-controlled, phase 2 study of the Janus Kinase 1 Inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa

Afsaneh Alavi, I. Hamzavi, K. Brown, L.L. Santos, Z.

Zhu, M.D. Howell, J. Kirby (Rochester/Ontario/Detroit/

Wilmington/Hershey)

What does/can the surgeon expect from the association of surgery with hidradenitis suppurativa-targeted medical treatments? A systematic review

Philippe Guillem (Écully)

Tumescence vs. general anesthesia - a precious alternative in large hidradenitis suppurativa surgery learned due to the COVID pandemic

Maurizio Podda (Darmstadt)

Reduction of wound healing disorders in surgical reconstruction of hidradenitis suppurativa with primary wound closure by therapy with adalimumab

G. Girbig, Natalie Kirsten, M. Augustin, M. Blessmann, K.

Grupp, F. Knoll (Hamburg)

15.00–18.00

Imaging technologies in hidradenitis suppurativa: from theory to the clinical practice

Antonio Martorell (Manises)

Thermography and Hyperspectral Imaging (HSI) modalities showing 3D-perfusion analysis for diagnosis and management of hidradenitis suppurativa/acne inversa

Thomas Wild, A. Aljowder, G. Daeschlein, K. Weissenberg, D. Cruz, C.C. Zouboulis (Dessau)

Ultrasound-guided photodynamic therapy with intralesional methylene blue and a 635 nm light-emitting diode lamp in hidradenitis suppurativa: a retrospective study of 41 patients

Marta Gamissans i Cañada, N. Riera Martí, J. Romani De Gabriel, Y. Gilaberte (Sabadell/Zaragoza)

18.00–19.00**Selected Poster Session – Poster Prizes****19.00–19.15****Conference Closing/Announcements**

POSTERS

EPIDEMIOLOGY AND DIAGNOSTIC TOOLS (CLINICAL PHENOTYPES, OUTCOMES MEASURES)

- 21 Do men and women have different clinical characteristics in HS ?
F. Benhadou (Belgium), A. P. Villani, D. Mintoff, P. Guillem,
- 25 Pain assessment in patients suffering from hidradenitis suppurativa
P. K. Krajewski (Poland), L. Matusiak, E. von Stebut, M. Schultheis, U. Kirschner, G. Nikolakis, J. C. Szepletowski
- 26 Increased odds of central sensitization in patients with hidradenitis suppurativa; a cross-sectional case-control study
P. Aarts (Netherlands), J. J. Aitken, K. R. van Straalen
- 27 Clinical features of pediatric- versus adult-onset hidradenitis suppurativa: results of a monocentric retrospective study
A. Di Cesare (Italy), E. Rosi, M. T. Fastame, S. Senatore, F. Ricceri, F. Prignano
- 29 Prevalence of Hidradenitis Suppurativa in a Population-based Dutch Cohort
L. M. Prens (Netherlands), K. Bouwman, L. Toelstra, E. P. Prens, B. Alizadeh, B. Horváth
- 40 A systematic review of pain measurement in skin conditions and rheumatoid arthritis to inform validation of a pain instrument for Hidradenitis Suppurativa (HS)
S. B. Hasan (UK), R. Gendra, J. James, D. Morris, L. Orenstein, J. R. Ingram
- 49 Stigmatization feeling in patients with hidradenitis suppurativa
P. Guillem (France), V. Vlaeminck-Guillem
- 57 Reproductive desires in patients with hidradenitis suppurativa: therapeutic implications
T. Montero-Vilchez (Spain), L. Salvador-Rodríguez, C. Cuenca-Barrales, S. Arias-Santiago, A. Molina-Leyva

- 68** **Pregnancy outcomes in patients with hidradenitis suppurativa**
R. Tannenbaum (USA), L. Fitzpatrick, J. Hsiao, A. Strunk, A. Garg
- 78** **HS does not always begin in youth: clinical characteristics of 16 late-onset HS patients**
M. Delage-Toriel (France), C. Pierre-Audigier, K. Jidar, P. - H. Consigny, A. Hovnanian, O. Join-Lambert, A. Nassif
- 83** **Risk of chronic kidney disease in patients with hidradenitis suppurativa**
N. Almuhanha (Canada), S. Tobe, R. Alhusayen
- 99** **Prevalence of Depression Among Children, Adolescents, and Adults with Hidradenitis Suppurativa**
R. Tannenbaum (USA), S. Wright, A. Strunk, A. Garg
- 113** **An educational film to explain hidradenitis suppurativa to patients and non physician careproviders - A nurse initiative**
C. Perat (France), P. Guillem
- 119** **Pain in hidradenitis suppurativa correlates with disease severity but also with gender and smoking**
F. Benhadou (Belgium), A. P. Villani, P. Guillem
- 129** **A comprehensive, patient-based approach to the clinical and molecular classification of complex, syndromic hidradenitis suppurativa phenotypes: a practical, translational framework**
C. Moltrasio (Italy), G. Genovese, S. Crovella, P. M. Tricarico, M. Boniotto, S. Garcovich, A. V. Marzano
- 131** **Identification of clinical categories in hidradenitis suppurativa based on clinical patient characteristics: results from a cluster analysis.**
A. Rondags (Netherlands), S. Arends, R. J. Volkerling, I. C. Janse, J. L. Dickinson-Blok, E. L. C. Schoonhoven, H. Bootsma, A. Spoorenberg, B. Horváth
- 140** **Superficial and deep sampling of the skin microbiome in hidradenitis suppurativa**
C. B. Ardon (Netherlands), L. Pardo Cortes, R. Kraaij, K. R. van Straalen, E. P. Prens
- 149** **The first affected site in hidradenitis suppurativa both suggests specific disease-triggering factors and predicts disease outcome**
A. P. Villani (France), F. Benhadou, P. Guillem
- 152** **Two cases of hidradenitis suppurativa in literature: the Colonel Aureliano Buendia from 'One hundred years of solitude' and his author Gabriel Garcia Marquez**
P. Guillem (France)

BASIC AND TRANSLATIONAL EXPERIMENTAL RESEARCH (GENETICS, IMMUNOLOGY, BIOMARKERS)

- 24** MCPIP1/Regnase-1 expression in the skin of hidradenitis suppurativa patients
P. K. Krajewski (Poland), W. SzukaÅ, A. Lichawska-Cieslar, L. Matusiak, J. Jura, J. C. Szepletowski
- 30** Polish language version of HiSQoL: psychometric assessments
P. K. Krajewski (Poland), L. Matusiak, M. Szepletowska, J. Rymaszewska, G. B. E. Jemec, J. Kirby, J. C. Szepletowski
- 33** SARS-CoV-2 seroprevalence in patients with hidradenitis suppurativa in Lithuania
V. Jariene (Lithuania), A. Bubilaite, V. Rimsaite, M. Adomaitis, V. Kucinskiene, S. Valiukeviciene
- 34** Increased expression of NCSTN, Notch and PI3K/AKT3 in hidradenitis suppurativa (HS)
T. Gambichler (Germany), S. Hessam, M. Skrygan, L. Scholl, M. Sand, E. Stockfleth, F. Bechara, T. Meyer
- 46** Mucosal Associated Invariant T (MAIT) cells and the IL-17 Lineage in Hidradenitis Suppurativa
J. Mac Mahon (Ireland), C. Gallagher, A. Hogan, A. M. Tobin
- 48** Linking Leukocyte Populations, Inflammation and Insulin Resistance in Hidradenitis Suppurativa
J. Mac Mahon (Ireland), C. Fitzmaurice, A. M. Tobin
- 63** Prevalence of connective tissue disorders among patients with hidradenitis suppurativa
R. Kjærsgaard Andersen (Denmark), A. Strunk, J. Boer, G. B. E. Jemec, A. Garg
- 65** Is hidradenitis suppurativa caused by gene-gene interactions?
R. Kjærsgaard Andersen (Denmark), L. Larsen, S. Clemmensen, J. Hjelborg, N. Ødum, G. B. E. Jemec, K. Christensen
- 75** Perception and knowledge of Hidradenitis Suppurativa in Greece: a cross-sectional study of 1301 individuals.
A. I. Liakou (Greece), M. Papadakis, A. G. Tsantes, K. A. Tsante, G. Kontochristopoulos, I. Marnelakis, A. Kapsiocha, A. Katoulis, S. Grigoriou, D. Rigopoulos
- 92** Down Syndrome in Hidradenitis Suppurativa: a systematic review of 4893 patients
S. A. Der Sarkissian (Australia), K. J. L. Wark, G. Cains, F. W. John, J. Woods
- 97** Can we define inclusion criteria cut-offs to minimize placebo bias in clinical trials of hidradenitis suppurativa?
T. Kanni (Greece), V. Tzanetakou, D. Stergianou, A. Bolanou, S. Micha, E. J. Giamarellos-Bourboulis
- 104** Hidradenitis suppurativa associated with multiple myeloma and plasmacytoma - a case report
M. Costa (Portugal), D. João, X. Wen, A. Massa
- 133** Serum IgE levels and atopic status of patients with hidradenitis suppurativa
C. Toliopoulos (Greece), M. Makris, M. Dalamaga, O. Efthymiou, C. Fokoloros, A. Katoulis

- 136** Identification of Critical Mediators and Pathways in Patients with Hidradenitis Suppurativa
R. Hambly (Ireland), S. Gatault, L. Iglesias Martinez, S. Kearns^S, H. Rea, V. Marasigan, K. Lynam-Loane, S. Kirthi, R. Hughes, P. Doran, W. Kolch, B. Kirby
- 143** Late diagnosis of hidradenitis due to the finding of advanced squamous cell carcinoma: case report and review...new concerns with anti-TNF-alpha therapy
R. F. Magalhães (Brazil), H. M. Guerra
- 151** The G-CSF pathway in hidradenitis suppurativa
K. Volk (Germany), T. - C. Brembach, D. Šimaitė, E. Bartnik, S. Cucinotta, A. Pokrywka, M. L. Irmer, J. Triebus, E. Witte-Händel, G. Salinas, T. Leeuw, H. - D. Volk, K. Ghoreschi, R. Sabat
- 157** Anti-Saccharomyces cerevisiae autoantibodies in hidradenitis suppurativa: prevalence and diagnostic value
A. Kinyó (Hungary), Z. Kádár, A. L. Kovács, P. Oláh, T. Berki, R. Gyulai

TREATMENT INNOVATIONS (CLINICAL TRIALS, SURGICAL TREATMENT)

- 6** Phase II, single-centre, randomised, double-blind, placebo-controlled clinical trial to determine the safety and efficacy of adult allogeneic mesenchymal stem cells from adipose tissue in the treatment of draining fistulas in patients with hidradenitis suppurativa (HidraQureS 2020)
A. Molina-Leyva (Spain), T. Montero-Vilchez, L. Salvador-Rodriguez, C. Cuenca-Barrales, O. Espinosa-Ibañez, A. Carrillo-Acosta, A. Cardesa-Gil, R. Mata-Alcazar-Caballero, S. Arias-Santiago
- 7** Deroofing as a surgical option in hidradenitis suppurativa: local and distant recurrences and implicated factors
V. Mora-Fernández (Spain), J. Verdaguer Faja, J. Bassas-Vila
- 10** Patients' Response Stratified by High-, Medium-, and Low-Abscess and Nodule Counts to an Adalimumab Treatment for Moderate to Severe Hidradenitis Suppurativa: Post-hoc, Real-world Data from the SOLACE Study
W. P. Gulliver (Canada), A. Alavi, M. C. Wiseman, M. J. Gooderham, J. Rao, M. S. Alam, K. A. Papp, O. Desjardins, C. Jean
- 15** Adalimumab dose intensification in refractory and flaring hidradenitis suppurativa
G. Murray (Ireland), J. Mac Mahon, A. M. Tobin
- 16** The Importance of Therapeutic Drug Monitoring in Hidradenitis Suppurativa
C. Ciudad Blanco (Spain), A. Rosell Díaz, L. M. Nieto Benito, R. Suárez Fernández
- 18** Is acne conglobata the opposite spectrum of hidradenitis suppurativa-especially when it responds well to adalimumab?
E. G. Tampouratzi (Greece), J. C. Katsantonis

- 32** Split-thickness skin graft (STSG) technique in surgical treatment of axillary hidradenitis suppurativa
K. Wójcicka (Poland), P. K. Krajewski, J. C. Szepietowski
- 35** A curious case of optic neuritis in HS patient, successfully treated with Adalimumab
A. Mambrin (Italy), N. Skroza, E. Tolino, N. Bernardini, I. Proietti, V. Balduzzi, A. Marchesiello, P. Maddalena, S. Volpe, C. Potenza
- 41** Characterizing the treatment of Hidradenitis Suppurativa disease - a single center experience
Z. Khamaysi (Israel), A. Hammoud
- 43** COVID-19 and treatment with biologics: Safety insights from the Phase 3 studies of secukinumab in patients with moderate-to-severe Hidradenitis Suppurativa
E. Muscianisi (Denmark), A. - C. Potocki, D. Keefe, N. Thomas, T. Kasperek, A. B. Kimball, A. B. Gottlieb, A. Alavi, Z. Regui, G. B. E. Jemec
- 44** Intralesional therapy under ultrasound guidance in hidradenitis suppurativa: The importance of ultrasound evaluation
R. D. Caposiena Caro (Italy), C. Tartaglia, C. Pensa, P. Rossi, L. Bianchi
- 45** Clinical and Power-Doppler ultrasound features related with persistence of fistulous tracts under treatment with adalimumab in hidradenitis suppurativa: four years of follow-up
R. D. Caposiena Caro (Italy), F. M. Solivetti, E. Candi, C. Tartaglia, C. Pensa, P. Rossi, L. Bianchi
- 55** Effectiveness and Safety of Secukinumab in Patients with Hidradenitis Suppurativa: Our Clinical Experience
F. J. Melgosa Ramos (Spain), R. García-Ruiz, E. M. Sánchez-Martínez, H. Gegúndez-Hernández, T. Díaz Corpas, M. P. Pérez García, F. J. Ferrando Roca, A. I. Zayas Gavilá, A. Mateu-Puchades
- 56** Switching from Adalimumab originator to biosimilar: clinical experience in hidradenitis suppurativa patients
T. Montero-Vilchez (Spain), A. Rodríguez-Tejero, M. Sanchez-Díaz, S. Arias-Santiago, A. Molina-Leyva
- 58** Antibiotic use in Hidradenitis Suppurativa: a practice survey
A. - C. Fougereuse (France), Z. Regui, G. ResoVerneuil
- 60** Comprehensive study of hidradenitis suppurativa in the perspective of pathogenesis and clinical and histological therapeutic efficacy of fractional microneedling radiofrequency
D. H. Kim (South Korea), J. H. Yang, S. I. Cha, J. Y. Yoon, J. Moon, J. W. Kim, S. Choi, D. H. Suh
- 61** Acne-like Hidradenitis Suppurativa or Acne Associated with Hidradenitis ? That is the Question ! Therapeutic Connections
V. Bettoli (Italy), G. Odorici

- 64** Current changes in the standard of care of HS patients in a German specialist clinic due to the COVID-19 pandemic
M. Kovacs(Germany), M. Podda
- 66** Adalimumab dose intensification in hidradenitis suppurativa: our real-life experience
E. M. Sánchez-Martínez (Spain), R. García-Ruiz, F. J. Melgosa-Ramos, H. Gegúndez-Hernández, A. Aguado-Vázquez, A. Mateu-Puchades
- 70** Drug repurposing for hidradenitis suppurativa treatment
C. C. Zouboulis (Germany), A. Nogueira da Costa
- 71** Therapeutic use of Cicaderma® in the management of surgical wounds
C. Perat (France), O. Raspado, S. Al Samman Zouaghi, T. Ghizzo, V. Lagrange, P. Guillem
- 73** Metformin for the treatment of hidradenitis suppurativa: our experience with 27 patients
J. M. Segura Palacios (Spain), M. Colmenero Sendra, J. del Boz González, F. Rivas Ruiz, M. de Troya Martín
- 74** Colchicine improves clinical outcomes and quality of life in hidradenitis suppurativa patients: a prospective study
A. I. Liakou (Greece), G. Kontochristopoulos, E. Agiasofitou, M. Papadakis, A. G. Tsantes, I. Marnelakis, K. A. Tsante, A. Kapsiocha, A. Katoulis, S. Grigoriou, D. Rigopoulos
- 77** Ultrasound pre-surgical mapping of hidradenitis suppurativa lesions: a pilot study
M. Iannone (Italy), T. Oranges, L. Balderi, B. B. Benincasa, G. Davini, G. Tonini, A. Janowska, M. Romanelli, V. Dini
- 79** Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after anti-TNF failure
E. C. Marques (Czech Republic), A. Smetanova, M. Arenbergerova
- 81** LAight®therapy is an effective treatment option in patients with hidradenitis suppurativa Hurley stage I and II: a multicenter randomized, controlled trial (RELIEVE)
M. Schultheis (Germany), P. Staubach, S. Grabbe, C. Ruckes, G. Nikolakis, E. von Stebut, U. Kirschner, L. Matusiak, J. C. Szepietowski
- 89** The role of negative pressure wound therapy in the management of axillary hidradenitis suppurativa
A. - C. Ezanno (France), M. Perez, A. - C. Fougerousse, P. Guillem, G. Resoverneuil
- 90** Cytokine Profile of Pus in Patients with Hidradenitis Suppurativa (HS): How it is Associated with Treatment Response to Cytokine Inhibitors
D. Stergianou (Greece), V. Tzanetakou, A. Bolanou, T. Kanni, S. Micha, S. Rellou, E. J. Giamarellos-Bourboulis
- 91** Impact of Plasma of Patients with Hidradenitis Suppurativa (HS) on Cytokine Production by Mononuclear Cells: Association with Response to Treatment
V. Tzanetakou (Greece), D. Stergianou, S. Micha, T. Kanni, A. Bolanou, E. J. Giamarellos-Bourboulis

- 103** Management of Challenging HS Cases from Lithuania
T. Raudonis (Lithuania), R. A. Vankeviciute, J. Grigaitiene, R. Ganceviciene
- 109** Effectiveness of doxycycline and rifampicin combination-therapy in hidradenitis suppurativa: a descriptive prospective study
J. Verdaguer Faja (Spain), V. Mora-Fernández, J. Bassas-Vila
- 120** Effect of Adalimumab on skin pain in patients with Hidradenitis Suppurativa: a systematic review and meta-analysis
A. Tsentemeidou (Greece), N. Sideris, E. Vakirlis, D. Ioannides, E. Sotiriou
- 121** Therapeutic drug level monitoring in patient with hidradenitis suppurativa
M. Alter (Germany)
- 125** Perifolliculitis capitis abscondens et suffodiens with hidradenitis suppurativa and nodulocystic acne treated with adalimumab
I. Kurokawa (Japan)
- 141** Adalimumab long-term survival in patients with moderate-to-severe Hidradenitis Suppurativa
E. Vilarrasa (Spain), C. López-Llunell, E. Agut-Busquet, F. Bittencourt, L. Puig, J. Romani
- 142** Facial hidradenitis suppurativa successfully treated with adalimumab
H. Cembrero Saralegui (Spain), F. Alfageme Roldán, M. Grau Pérez, L. Turrión Merino, M. Elosua González, E. López-Negrete Arenal, R. Cabeza Martínez, M. Sigüenza Sanz, G. Roustán Gullón¹
- 163** Biologic therapy is not associated with increased COVID-19 severity in HS: Preliminary findings from the Global Hidradenitis Suppurativa COVID-19 Registry
H. B. Naik (USA), R. Alhusayen, S. Guilbault, J. R. Ingram, M. V. Kudlinski, M. A. Lowes, A. V. Marzano, M. Paul, B. Villumsen, C. A. Yannuzzi
- 167** Switching from biosimilar Adalimumab to originator Adalimumab and vice versa as an alternative to target switch in patients with Hidradenitis Suppurativa: a single center experience.
F. Alfageme (Spain), H. Cembrero, I. Salguero, M. Hospital, C. Martinez, G. Roustandi

EHSF SPONSORS

We would like to thank all our sponsors for their support and are looking forward to further collaboration!

PLATINUM SPONSOR

The Abbvie logo, consisting of the word "abbvie" in a lowercase, sans-serif font, is centered within a white square. This square is set against a dark blue background that has a subtle, lighter blue grid pattern.

SILVER SPONSORS



FIND OUT ABOUT THE LATEST PRODUCTS AND DEVELOPMENTS.

Digital Lounges

- Visit our sponsors in their digital hospitality lounges!

Chat and Video Chat

- Start a conversation and meet your personal contact simply by using the chat and video chat function



GENERAL INFORMATION

Scientific Organizer

European Hidradenitis Suppurativa
Foundation e.V.

Auenweg 38, 06847 Dessau-Rosslau
www.ehsf.eu

Prof. Dr. Christos C. Zouboulis
President of the EHSF e.V.

Professional Congress Organizer

MCI Deutschland GmbH
Markgrafenstrasse 56
10117 Berlin

T: +49 30 20459230

F: +49 30 2045950

Contact

Project Management
Viktoria Solotar
T: +49 30 20459374
ehsf@mci-group.com

Sponsoring/Exhibition
Judith Lange
T: +49 30 20459320
ehsf-sponsoring@mci-group.com

WEBINAR SERIES

abbvie

360° Perspectives on Challenging HS Cases: What happened next?

Wednesday, 10 February 2021

Join us for our webinar series and find out from a panel of 14 international expert dermatologists specializing in hidradenitis suppurativa (HS) what happened after these patients started treatment.



Sofia

Highly inflammatory

10:00 CET

Dr. Ruaa Al Harithy
(Saudi Arabia)

Dr. Pierre-André Becherel
(France)

Dr. Nobukazu Hayashi (Japan)

Dr. Maria Cecilia Rivitti
Machado (Brazil)

Dr. Laura Savage (UK)

Dr. Thrasyvoulos Tzellos
(Norway)

Dr. Hessel van der Zee
(Netherlands)



Adam

Combination therapy

14:00 CET

Dr. Monika Arenbergerova
(Czechia)

Dr. Falk Bechara (Germany)

Dr. Vincenzo Bettoli (Italy)

Dr. Antonio Martorell (Spain)

Dr. Lukasz Matusiak
(Poland)

Dr. Saxon Smith (Australia)

Dr. Mariano Suppa
(Belgium)

WATCH WEBINAR

ALL-HUMD-210016

